iShares MSCI Indonesia ETF vs Mesoblast Limited — how do they compare? iShares MSCI Indonesia ETF trades at $12.47, while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: Mesoblast Limited is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals.
| EIDO | MESO | |
|---|---|---|
52-Week High | $19.22 | $20.96 |
52-Week Low | $10.80 | $12.88 |
Market Cap | — | $2.21B |
Sector | — | Technology |
Enterprise Value | — | $2.21B |
Trailing returns across standard periods
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →